Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
niraparib
- Development stage
- Approved
- Lead developer
- GSK
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Niraparib is an orally active small molecule inhibitor of poly (ADP-ribose) polymerase (PARP), specifically targeting PARP-1 and PARP-2 enzymes. By inhibiting these enzymes, which are involved in DNA repair, niraparib induces cytotoxicity in cancer cells—particularly those with deficiencies in homologous recombination repair mechanisms such as BRCA mutations. Niraparib is primarily indicated for the maintenance treatment of adult patients with advanced or recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who have responded to platinum-based chemotherapy. It has also been approved in combination with abiraterone and prednisone/prednisolone for certain cases of metastatic castration-resistant prostate cancer associated with BRCA mutations.
- Brand names
- Zejula
- Other names
- niraparibZejula
02
Targets
PARP1 (Poly (adp-ribose) polymerase 1)PARP2 (Poly (adp-ribose) polymerase 2)MAT (Monoamine transporters)
Beyond the preview
Go deeper on niraparib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on niraparib.